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ABSTRACT
Understanding functional interactions between DCs and antigens is necessary 
for achieving an optimal and desired immune response during vaccine development. 
Here, we identified and characterized protein Rv2299c (heat-shock protein 90 
family), which effectively induced DC maturation. The Rv2299c-maturated DCs 
showed increased expression of surface molecules and production of proinflammatory 
cytokines. Rv2299c induced these effects by binding to TLR4 and stimulating the 
downstream MyD88-, MAPK- and NF-κB-dependent signaling pathways. The Rv2299c-
maturated DCs also showed an induced Th1 cell response with bactericidal activity and 
expansion of effector/memory T cells. The Rv2299c-ESAT-6 fused protein had greater 
immunoreactivity than ESAT-6. Furthermore, boosting BCG with the fused protein 
significantly reduced hypervirulent Mycobacterium tuberculosis HN878 burdens post-
challenge. The pathological study of the lung from the challenged mice assured the 
efficacy of the fused protein. The fused protein boosting also induced Rv2299c-ESAT-
6-specific multifunctional CD4+ T-cell response in the lungs of the challenged mice. 
Our findings suggest that Rv2299c is an excellent candidate for the rational design 
of an effective multiantigenic TB vaccine.
INTRODUCTION
Mycobacterium tuberculosis (Mtb) is one of the 
most successful human pathogens, with one-third of the 
world’s population being infected [1]. Because the only 
available vaccine, M. bovis Bacillus Calmette Guerin 
(BCG), is unable to provide significant protection against 
tuberculosis (TB) in adults [2], a more effective vaccine 
for replacing or boosting BCG is clearly needed. Currently, 
one of the reigning strategies in TB vaccine research is to 
develop BCG-booster vaccines using adjuvanted protein 
subunits. These heterologous prime-boost strategies have 
proven a powerful mode of vaccination. It is important 
to identify and characterize the mycobacterial antigens 
involved in the induction of protective immunity for 
effective development of prospective TB vaccine 
candidates. However, there are few antigens that have 
been used in preparation of TB vaccines that are currently 
in various phases of clinical trials [3].
Th1 immune responses are essential for controlling 
Mtb infection. Disruption of genes involved with Th1-related 
cytokines such as IFN-γ and IL-12 increases the susceptibility 
to mycobacterial infection in mice and humans [4]. Therefore, 
many studies on TB vaccines have been focused on strong 
T-cell-stimulating antigens, such as antigen 85 complex 
(Ag85) and ESAT-6 [5]. T-cell responses, which are essential 
for controlling infection, rarely eliminate Mtb from infected 
humans or animals [6-8]. Although strong T-cell-stimulating 
antigens induce robust protective immunity in mice, these 
antigens cannot induce complete sterilizing immunity [9, 10].
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Dendritic cells (DCs), the most professional antigen-
presenting cells in the immune system, are key players 
involved in bridging the innate and adaptive immunity. 
It has been suggested that Mtb subverts CD4 T-cell-
dependent immunity by delaying initiation of T-cell 
responses via modulation of DC functions [11-14] and 
survives in a dormant form. Therefore, early activation and 
migration of DCs to draining lymph nodes together with 
stimulation of T cells are key factors for inducing effective 
protection against Mtb infection. These observations 
suggest that a mycobacterial antigen that elicits effective 
host protective immunity via DC activation is a promising 
target for development of a TB vaccine. In fact, DCs 
infected with BCG or pulsed with Mtb antigens induce 
significant protection to a challenge with both moderate 
and high doses of virulent Mtb in a mouse model [15, 
16]. Although several mycobacterial proteins that activate 
DCs to drive a Th1 immune response have been identified, 
little is known about their detailed antimycobacterial 
mechanism and about protective efficacy of the protein 
itself as a vaccine.
ESAT-6-containing vaccines such as H1 or H56 
have been demonstrated to confer efficient protection 
against Mtb H37Rv in pre- or post-exposure animal 
models, and the fusion protein is more protective than 
either component [10, 17]. Here, we hypothesized that 
incorporating DC-activating protein would improve 
long-term efficacy of the vaccine containing only T-cell 
antigens. Because DCs maturated by a DC-activating 
protein are an effective antigen-presenting cell for 
generation of a long-term Th1 memory response against 
a T-cell-stimulating antigen, and the DC-activating 
protein itself can strongly drive Th1 polarization. It has 
been reported that mycobacterial heat-shock proteins 
(HSPs) including HSP65 induce strong protective 
immunity against TB [18]. In this study, we identified 
the Rv2299c protein (belongs to the HSP90 family), 
which effectively induced DC maturation, and then we 
analyzed its antimycobacterial mechanism through DC 
activation to elicit strong Th1-type responses. Next, 
we tested protective vaccine efficacy of the Rv2299c 
protein or Rv2299c-fused ESAT-6 protein against 
Mtb HN878 clinical isolates. Our results suggest that 
Rv2299c-maturated DCs induce a Th1 cell response 
with antimycobacterial activity, and the fusion protein 
consisting of Rv2299c and ESAT-6—as a new concept of 
a DC-activating protein-based vaccine—is a promising 
way of boosting BCG.
RESULTS
The recombinant Rv2299c protein induces 
maturation and activation of DCs
There is little information about the im-
munological roles of the Rv2299c protein in the 
mycobacterial HSP family. We purified the recombinant 
Rv2299c protein in Escherichia coli BL21 to study its 
immunoreactivity. Purity of Rv2299c was assessed 
by SDS-PAGE and western blot analysis (Figure 1A). 
Endotoxin content of prepared Rv2299c was below 
15 pg/ml (<0.1 EU/ml) according to an LAL assay. 
DCs and macrophages play a major role in initiation 
and activation of the protective immune response to 
mycobacteria. Therefore, we examined the effect of 
Rv2299c on macrophage activation or DC maturation. 
Rv2299c activated both DCs and macrophages, but 
the increase in the amount of cytokine secretion was 
more dramatic in the DCs than in the macrophages 
(data not shown). Endocytic activity as a marker of 
DC maturation was measured by exposure to dextran-
fluorescein isothiocyanate (FITC). Double-positive cells 
(CD11c+ and dextran-FITC-positive) were decreased 
in number among DCs treated with Rv2299c or 
lipopolysaccharide (LPS), which served as a positive 
control, indicating that endocytic activity was reduced 
and functional maturity was enhanced by this protein 
(Figure 1B). Furthermore, DCs treated with Rv2299c 
for 24 hr showed strongly enhanced expression of MHC 
classes I and II and of costimulatory molecules such as 
CD80 and CD86 in a dose-dependent manner (Figure 
1C). These results suggest that Rv2299c efficiently 
induces DC maturation.
Some studies have shown that DC-derived 
cytokines stimulate the polarization of T cells and 
inflammatory responses [19]. Therefore, next, we tested 
whether DC maturation by Rv2299c was coupled with 
the secretion of pro- or anti-inflammatory cytokines. As 
shown in Figure 1D, Rv2299c significantly stimulated 
DCs to secrete large amounts of TNF-α, IL-6, and IL-
1β, whereas untreated DCs secreted negligible amounts 
of these cytokines. We then determined the production 
of IL-12p70 and IL-10, which have an important effect 
on the development of T-cell immune responses. Unlike 
LPS, Rv2299c significantly induced the secretion of IL-
12p70, but not IL-10 (Figure 1D). Fluorescence-activated 
cell sorting (FACS) analysis also revealed that DCs 
treated with Rv2299c showed an increased percentage 
of IL-12p70-positive cells as compared to untreated 
DCs, while no change was found in IL-10-positive cells 
(Figure 1E). Although endotoxin content was monitored 
all the time during the preparation of the recombinant 
protein, we further assessed LPS contamination by 
treatment with proteinase K or heat denaturation, 
which abrogated the ability of Rv2299c to trigger DC 
maturation (Supplementary Figure 1). The effects of 
Rv2299c were not inhibited by polymyxin B treatment, 
whereas those of LPS were significantly inhibited. Taken 
together, these results suggest that Rv2299c induces 
secretion of proinflammatory cytokines from DCs, and 
these Rv2299c-matured DCs may promote a Th1-type 
immune response.
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Rv2299c induces DC maturation via the TLR4 
pathway
Several Mtb components that activate DCs via a 
Toll-like receptor (TLR) pathway have been identified 
[20]. Therefore, we determined whether Rv2299c 
could be recognized by, and act through, TLRs in DCs. 
The expression of surface molecules (Figure 2A) and 
proinflammatory-cytokine secretion (Figure 2B) were 
significantly suppressed in DCs from TLR4−/− mice when 
compared to DCs from wild-type (WT) or TLR2−/− mice, 
indicating that Rv2299c may be an agonist of TLR4 in 
Figure 1: Recombinant Rv2299c induces DC maturation. A. Purified recombinant Rv2299c protein was analyzed by SDS-
PAGE with Coomassie blue staining (a) and western blot analysis using anti-His antibodies (b). DCs were activated with the indicated 
concentration of Rv2299c or LPS (100 ng/ml) for 24 hr. B. Activated DCs were incubated with dextran-FITC at 37°C or 4°C for 30 min and 
assessed by FACS analysis of dextran (FITC) uptake. The percentages of dextran (FITC)-positive CD11c (PE)-positive cells are indicated. 
The results are representative of the results of four experiments. Bar graphs show mean ± SEM of four experiments. C. Activated DCs 
were stained with an anti-CD80, anti-CD86, anti-MHC class I, or anti-MHC class II Ab and analyzed for expression of surface markers. 
Bar graphs show the percentages (mean ± SEM of five separate experiments) for each surface molecule on CD11c+ cells. D. TNF-α, IL-
6, IL-1β, IL-12p70, and IL-10 levels in the culture medium were measured by an ELISA. Data are presented as mean ± SEM (n = 5). E. 
Dot plots of intracellular IL-12p70 and IL-10 expression in CD11c+ DCs. *p < 0.05, **p < 0.01, and ***p < 0.001 for treated compared to 
untreated DCs (CON).
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DCs. MyD88 is a common adaptor molecule to all the 
TLRs, whereas TRIF is essential for TLR4 signaling 
pathway [21]. Determination of proinflammatory-
cytokine production in DCs from WT, MyD88−/−, and 
TRIF-deficient mice suggested that a MyD88- and TRIF-
dependent signaling pathway was involved in Rv2299c-
induced production of TNF-α, IL-6, and IL-1β (Figure 
2C). Next, we tested whether Rv2299c binds to TLR4 
Figure 2: Rv2299c induces DC activation via TLR4. Bone marrow-derived DCs from WT, TLR2−/−, and TLR4−/− mice were treated 
with Rv2299c (10 μg/ml) or LPS (100 ng/ml) for 24 hr. A. Expression of CD86 and MHC class II was determined by staining and flow 
cytometry. Bar graphs show the percentages (mean ± SEM of three separate experiments) for each surface molecule on CD11c+ cells. 
B. and C. DCs derived from WT, TLR2−/−, or TLR4−/− and WT, MyD88−/−, or TRIF−/− mice were stimulated with Rv2299c or LPS for 24 hr 
and the produced cytokines were determined by an ELISA. D. Fluorescence intensity of the anti-His antibody bound to Rv2299c-treated 
DCs. DCs derived from WT, TLR2−/−, and TLR4−/− mice were treated with Rv2299c (10 μg/ml) for 1 hr, fixed, and stained with DAPI and 
a Cy3-conjugated anti-His antibody (Scale bar: 10 mm). E. DCs treated with Rv2299c for 1 hr and stained with an Alexa 488-conjugated 
anti-His mAb. Representative flow cytometry (left). The percentage of positive cells shown in each panel are also presented as mean ± 
SEM of three independent experiments (right). ISO: isotype control. F. DCs were treated with Rv2299c (10 μg/ml) for 6 hr. The cells were 
harvested, and cell lysates were immunoprecipitated (IP) with an anti-rat IgG, anti-mouse IgG, anti-His, anti-TLR2, or anti-TLR4 Ab; then 
proteins were visualized by immunoblotting (IB) with anti-His, anti-TLR2, or anti-TLR4 Abs. Totals are shown as mean total cell lysates 
(input). All data are expressed as mean ± SD (n = 3). One representative data point of three experiments is shown; *p < 0.05, **p < 0.01 
and ***p < 0.001 for different treatments compared to Rv2299c- or LPS-treated WT DCs.
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in DCs. Confocal microscopy with an Cy3-conjugated 
anti-His antibody (Ab) revealed that Rv2299c bound 
preferentially to the surface of WT and TLR2−/− DCs 
but not TLR4−/− DCs (Figure 2D). The binding between 
Rv2299c and the TLR4 molecule was also confirmed 
by FACS analysis (Figure 2E). To further confirm the 
binding between Rv2299c and TLR4, we performed 
immunoprecipitation analysis with an anti-TLR2 or anti-
TLR4 Ab and an anti-His Ab. We found that Rv2299c 
binds to TLR4, but not TLR2 (Figure 2F). These findings 
clearly revealed that Rv2299c induced DC maturation in 
a TLR4-dependent manner, causing increased expression 
of cell-surface molecules and proinflammatory cytokines.
MAPK and NF-κB pathways are involved in 
Rv2299c-mediated DC maturation
MAPKs and NF-κB are important signaling 
molecules for controlling the maturation of DCs and 
for secretion of proinflammatory cytokines [22, 23]. 
We therefore examined the activation of MAPKs and 
NF-κB in response to Rv2299c. As expected, Rv2299c 
triggered phosphorylation of p38 and ERK1/2 as well 
as phosphorylation and degradation of IκB-α in DCs 
(Figure 3A), and induced significant translocation of p65 
from the cytosol to the nucleus (Figure 3B). To confirm 
the activation of MAPKs and NF-κB in Rv2299c-induced 
Figure 3: Involvement of the ERK1/2 and p38 but not JNK pathways in Rv2299c protein-induced maturation of 
DCs. A. Protein production by DCs treated with Rv2299c for indicated periods was analyzed by immunoblotting using each specific Ab: 
to phospho-p38 (p-p38), p38, phospho-ERK1/2 (p-ERK1/2), phospho-IκB-a, IκB-a, and p65 NF-κB. B. Effects of Rv2299c on cellular 
localization of the p65 subunit of NF-κB in DCs. DCs were plated in covered glass chamber slides and treated with Rv2299c for 1 hr, 
and immunoreactivity of the p65 subunit of NF-κB in cells was determined by immunofluorescence. C. and D. DCs were pretreated with 
pharmacological inhibitors of p38 (SB203580, 20 μM), ERK1/2 (U0126, 10 μM), JNK (SP600125, 20 μM), Bay11-7082 (5 μM), or DMSO 
(vehicle control) for 1 hr prior to treatment with 10 mg/ml Rv2299c protein for 24 hr. The expression of CD80 and CD86 was analyzed by 
flow cytometry (C). Bar graphs show the percentages (mean ± SEM of three separate experiments) for each surface molecule on CD11c+ 
cells. The amounts of TNF-α, IL-6, and IL-1β in the culture medium were measured by ELISAs (D). The mean ± SEM are shown for three 
independent experiments; *p < 0.05, **p < 0.01, or ***p < 0.001 for inhibitor treatments compared to Rv2299c-treated controls.
Oncotarget19952www.impactjournals.com/oncotarget
proinflammatory cytokine production and costimulatory 
molecule expression, DCs were pretreated with a p38 
inhibitor (SB203580), an ERK1/2 inhibitor (U0126), a 
JNK inhibitor (SP600125), or an NF-κB inhibitor (Bay 
11-0782) for 1 hr before exposure to Rv2299c. All the 
pharmacological inhibitors except the JNK inhibitor 
significantly suppressed Rv2299c-induced expression 
of the costimulatory molecules on the surface of DCs 
(Figure 3C) and the production of proinflammatory 
cytokines (Figure 3D). Based on these findings, we 
believe that the MAPK and NF-κB signaling pathways 
are essential for production of proinflammatory cytokines 
and for expression of DC maturation markers induced by 
Rv2299c.
Rv2299c-maturated DCs induce naïve-T-cell 
proliferation
To precisely characterize Rv2299c activity on the 
interaction between DCs and T cells, we performed a 
syngeneic in vitro T-cell proliferation assay using OT-I 
T cell receptor (TCR) transgenic CD8+ T cells and OT-II 
TCR transgenic CD4+ T cells. DCs pulsed with OVA257–264 
or OVA323–339 were cocultured with transgenic CFSE-
labeled OVA-specific CD4+ or CD8+ T cells for 72 hr. 
Rv2299c- or LPS-treated DCs induced T-cell proliferation 
to a significantly greater extent as compared to untreated 
DCs (Figure 4A). Furthermore, naïve CD4+ and CD8+ 
T cells primed with Rv2299c-treated DCs produced 
significantly greater IFN-γ and IL-2 amounts than did 
those with untreated DCs, whereas IL-4 secretion did not 
increase regardless of Rv2299c stimulation (Figure 4B). 
These results suggest that the Rv2299c-treated DCs direct 
naïve-T-cell proliferation toward a Th1 phenotype.
Rv2299c-maturated DCs induce expansion of the 
effector/memory T-cell population
To determine whether Rv2299c-stimulated DCs 
have an ability to specifically stimulate CD4+ from 
Mtb-infected mice, we analyzed the expression change 
of CD62L and CD44 on CD4+ splenic T cells induced 
by Rv2299c-treated DCs using flow cytometry. DCs 
were prepared from the bone marrow of WT, TLR2−/−, 
or TLR4−/− mice and maturated with Rv2299c or LPS. 
After coculture of the Rv2299c-maturated DCs and 
syngeneic CD4+ T cells from the infected mice, Rv2299c-
maturated DCs from WT or TLR2−/− mice but not from 
TLR4−/− mice caused significantly downregulated CD62L 
and upregulated CD44 expression in CD4+ T cells when 
compared to control DCs or LPS-treated DCs (Figure 
5A). The percentages of CD4-IFN-γ- or CD4-IL-2-
positive cells were significantly higher for coculture with 
Rv2299c-maturated DCs from WT or TLR2−/− mice but 
not TLR4−/− mice when compared to control DCs or LPS-
stimulated DCs (Figure 5B). In addition, the numbers of 
CD4-IL-4-positive cells were not increased by coculturing 
with the antigen-stimulated DCs. These data suggest that 
Rv2299c-maturated DCs induce the expansion of effector/
memory T cells and drive Th1 immune responses in a 
TLR4-dependent manner.
T cells activated by Rv2299c-maturated DCs 
inhibit intracellular Mtb growth
To confirm that Rv2299c-maturated DCs actually 
play a role in the control of Mtb, we tested whether T cells 
activated by Rv2299c-maturated DCs could enhance the 
bactericidal activity of macrophages. Naïve splenic T cells 
from uninfected mice were activated by coculturing with 
Rv2299c-maturated DCs for 72 hr, and then added to Mtb-
infected bone marrow-derived macrophages (BMDMs). 
As shown in Figure 6A, the simple addition of unactivated 
T cells elicited a considerable inhibition of intracellular 
Mtb growth. Interestingly, T cells activated by Rv2299c-
maturated DCs significantly inhibited the Mtb growth as 
compared to T cells activated by unactivated DCs or LPS-
maturated DCs. Proinflammatory cytokines such as IFN-γ 
and IL-17, which are related to antimycobacterial activity, 
showed significantly higher expression levels during the 
addition of T cells activated by Rv2299c-maturated DCs 
in comparison with that observed with the addition of 
T cells activated by unactivated DCs or LPS-maturated 
DCs. These data indicated that inhibition of Mtb growth is 
induced by the production of these cytokines (Figure 6B). 
Significant IFN-γ and IL-2 production was induced by 
addition of T cells activated by unactivated DCs or LPS-
maturated DCs as compared to addition of T cells only. 
These results suggest that Rv2299c induces activation of 
the T cells with bactericidal activity via DC maturation.
Fusion of Rv2299c to ESAT-6 enhances the 
immunoreactivity of ESAT-6
We hypothesized that a DC-activating protein can 
enhance the protective immunity of a T-cell-stimulating 
antigen. To test this notion, ESAT-6, a major T-cell vaccine 
candidate, was expressed and purified as a protein fused to 
Rv2299c in E. coli, and its immunogenicity was assessed. 
First, we determined the cytotoxicity of the recombinant 
Rv2299c-ESAT-6 fusion protein in BMDMs by annexin 
V and propidium iodide (PI) staining. ESAT-6 showed 
cellular toxicity at a concentration above 5 μg/ml, but the 
fusion protein did not exert toxicity at 20 μg/ml (Figure 
7A). Therefore, ESAT-6 was used at the concentration 
of 2 μg/ml in subsequent experiments. Next, we further 
assessed LPS contamination by treatment with proteinase 
K or heat denaturation, which abrogated the ability of 
Rv2299c-ESAT-6 fusion protein to trigger DC maturation 
(Supplementary Figure 2). The effects of Rv2299c 
were not inhibited by polymyxin B treatment, whereas 
those of LPS were significantly inhibited. Expression 
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of costimulatory and MHC molecules (Figure 7B) and 
production of proinflammatory cytokines such as TNF-α, 
IL-1β, and IL-12 (Figure 7C) was significantly increased 
in DCs stimulated with the fusion protein in comparison 
with a single protein. Next, we also determined bactericidal 
activity of T cells stimulated by the fusion protein-maturated 
DCs. As shown in Figure 8A, intracellular Mtb growth was 
significantly inhibited by addition of T cells activated with 
ESAT-6-maturated DCs as compared to control BMDMs 
without any T cells or DCs. Nevertheless, T cells activated 
by Rv2299c-stimulated DCs or Rv2299c-ESAT-6 fusion 
protein-maturated DCs significantly inhibited the growth 
of intracellular Mtb as compared to any other condition. 
The highest production of proinflammatory cytokines 
such as IFN-γ and TNF-α was detected when Mtb-infected 
BMDMs were cocultured with T cells activated by the 
fusion protein-stimulated DCs (Figure 8B). IL-4 production 
was not detected in any condition (data not shown).
Figure 4: Rv2299c protein-treated DCs induce T-cell proliferation. A. Transgenic OVA-specific CD8+ T cells and transgenic 
OVA-specific CD4+ T cells were isolated, stained with CFSE, and cocultured for 96 hr with DCs treated with Rv2299c (10 μg/ml) or LPS 
(100 ng/ml), then pulsed with OVA257–264 (1 μg/ml) for OVA-specific CD8
+ T cells or OVA323–339 (1 μg/ml) for OVA-specific CD4
+ T cells, 
respectively. T cells only and T cells cocultured with untreated DCs served as controls. The proliferation of OT-I+ and OT-II+ T cells was 
then assessed by flow cytometry. B. The culture supernatants harvested after 24 hr and IFN-γ, IL-2, and IL-4 were assayed by ELISA. The 
mean ± SEM is shown for three independent experiments; *p < 0.05 for treatments when compared to the appropriate controls (T cell/
OVA257–264 pulsed DCs or T cell/OVA323–339 pulsed DCs). n.s.: no significant difference.
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The Rv2299c-ESAT-6 fusion protein has 
significant BCG prime boosting effects against 
the hypervirulent HN878 strain
Finally, we determined whether the Rv2299c-
ESAT-6 fusion protein has a vaccine potential against 
TB. First, to determine the value of Rv2299c as a 
vaccine antigen, protective efficacy of Rv2299c alone in 
prophylactic settings was evaluated against Mtb Erdman. 
However, vaccination with Rv2299c/MPL-DDA did not 
confer significant protection against Erdman in terms 
of reduction of bacterial burden in the lungs and spleen 
(data not shown). We next demonstrated the level of 
protection against an Mtb HN878 challenge provided by 
Figure 5: Rv2299c protein-treated DCs induce expansion of effector/memory T-cell population. DCs from WT, TLR2−/−, 
and TLR4−/− mice were treated with Rv2299c (10 μg/ml) or LPS (100 ng/ml), and then cocultured for 3 d with T cells from Mtb-infected 
mice at DC to T cell ratios of 1:10. Splenocytes were stained with anti-CD4, anti-CD62L, and anti-CD44 mAbs. A. A histogram is shown 
for gating of the labeled T cells. Bar graphs show CD62LlowCD44high T cells or CD62LhighCD44low T-cell populations among the spleen 
cells. B. Intracellular IFN-γ, IL-2, or IL-4 expression in CD3+/CD4+ T cells cocultured with untreated DCs, Rv2299c-treated DCs, or 
LPS-stimulated DCs. The percentages of CD3+/CD4+ T cells among all T cells are indicated in the top right corner. Mean ± SEM for three 
independent experiments is shown; **p < 0.01 or ***p < 0.001 for treatments compared to untreated DCs. n.s.: no significant difference.
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immunization with the Rv2299c-ESAT-6 fusion protein 
as a BCG-prime booster. Previous studies showed that 
BCG vaccination of mice provides less protection 
against W-Beijing isolates than against Mtb H37Rv over 
10 weeks postinfection [24]. Therefore, we tested the 
vaccine efficacy of the protein in a murine model using 
the clinical hypervirulent HN878 strain, belonging to 
the W-Beijing family, as described previously [25]. Four 
weeks after final vaccination, we challenged the mice 
with the Mtb HN878 strain and determined the bacterial 
loads in their lungs 16 weeks postchallenge (Figure 9A). 
As shown in Figure 9B, BCG only, ESAT-6, and the 
Rv2299c-ESAT-6 fusion protein (separately) significantly 
reduced the bacterial loads in the lungs as compared to 
adjuvant control. There was no significant difference in 
protective efficacy among these three vaccines, although 
the ESAT-6 immunized group showed a higher bacterial 
load and worse pathological findings in the lungs. We 
Figure 6: T cells activated by Rv2299c-maturated DCs inhibit intracellular Mtb growth. Naïve T cells or T cells activated 
by unstimulated DCs, LPS-stimulated DCs, or Rv2299c-stimulated DCs at a DC:T cell ratio of 1:10 for 3 d were cocultured with BMDMs 
infected with Mtb. A. Intracellular Mtb growth in BMDMs was determined at time point 0 (0 day) and 3 d after coculturing with T cells or 
without T cells (control). B. The cytokine levels in culture supernatants were measured by ELISA. The data shown are the mean values ± 
SD (n = 3); *p < 0.05, **p < 0.01, or ***p < 0.001 for BMDMs cocultured with T cells compared to control BMDMs. n.s.: no significant 
difference.
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also evaluated the ability of the fusion protein to boost 
the BCG vaccine. Sixteen weeks after infection, the 
fusion protein-boosted mice had a significantly lower 
bacterial count than the BCG-vaccinated mice did. 
Overall, the Rv2299c-ESAT-6 fusion protein showed 
protective efficacy against an HN878 strain challenge in 
terms of bacterial count reduction at distant time points. 
In addition, at 16 weeks postchallenge, the Rv2299c-
ESAT-6 fusion protein-immunized group showed 
significantly reduced lung inflammation as compared 
with the infection control group (p < 0.01; Figure 9C 
and 9D).
Figure 7: Immunoreactivity of Rv2299c-ESAT-6 fusion protein. A. BMDCs treated with the indicated concentration of ESAT-6 
or Rv2299c-ESAT-6 fusion protein for 24 hr were analyzed by flow cytometry using staining with anti-CD11c, annexin V, and PI. 
Staurosporine was used as a positive control. The results are representative of three experiments. B. BMDCs treated with ESAT-6 (2 μg/ml), 
Rv2299c (10 μg/ml), or the Rv2299c-ESAT-6 fusion protein (1, 5, 10 μg/ml) for 24 hr were analyzed by two-color flow cytometry. The 
cells were gated to exclude CD11c cells. DCs were stained with anti-CD40, anti-CD80, anti-CD86, or anti-MHC class II. The results are 
representative of the results of three experiments. Bar graphs show mean ± SEM (n = 5). C. The cytokine levels in culture supernatants 
were measured by ELISA. Data are presented as mean ± SEM (n = 5); *p < 0.05, **p < 0.01, and ***p < 0.001 for different treatments 
compared to untreated control (CON).
Oncotarget19957www.impactjournals.com/oncotarget
Antigen-specific Th1 immune responses in mice 
infected with Mtb HN878
The Th1-mediated immune response and 
multifunctional T cells play important roles in protective 
immunity against Mtb. Thus, we next evaluated the change 
in the T-cell phenotype induced by Rv2299c-ESAT-6 
fusion protein immunization. Postchallenge, spleen and 
lung cells were stimulated in vitro with ESAT-6, Rv2299c, 
or the fusion protein, and the phenotypes of the responding 
CD4+ T cells were evaluated by multicolor intracellular 
cytokine staining and flow cytometry (Supplementary 
Figure 3). Increased numbers of triple-positive CD4+ T 
cells (coexpressing IFN-γ, TNF-α, and IL-2) in the lungs 
(Figure 10) and spleens (Supplementary Figure 4) were 
observed in the BCG/Rv2299c-ESAT-6 fusion protein-
immunized group (group 4) only (not in other groups). In 
addition, the Rv2299c-ESAT-6 fusion protein-immunized 
group showed an increased frequency of double-positive 
multifunctional CD4+ T cells (TNF-α+IL-2+ CD4+ and 
IFN-γ+IL-2+ CD4+ T cells) and single-positive (IL-2+ 
CD4+) T cells in the lungs and spleens postchallenge.
DISCUSSION
Subunit protein vaccines are potentially useful for 
BCG replacement or for boosting BCG-induced immune 
responses [26]. Here, we presented a vaccine strategy 
designed to improve protective efficacy of TB vaccine 
candidates. The selection of optimal antigens to be 
included in a polyprotein vaccine is the most important 
step for vaccine development. DCs regulate naïve-T-cell 
polarization and subsequent development of a Th1- or 
Th2-type response in a draining lymph node. Therefore, 
a DC-activating protein-based vaccine may enhance 
protective immunity of other antigens in the formulation. 
In this study, we found that the Rv2299c protein capable 
Figure 8: Inhibition of intracellular Mtb growth by T cells activated with Rv2299c-ESAT-6 fusion protein-maturated 
DCs. Naïve T cells or T cells activated by unstimulated DCs, ESAT-6-stimulated DCs, Rv2299c-stimulated DCs, or the fusion protein-
stimulated DCs at a DC:T cell ratio of 1:10 for 3 d were cocultured with BMDMs infected with Mtb. Intracellular Mtb growth in BMDMs 
A. and the cytokine levels B. were determined as in Figure 6. The data shown are mean values ± SD (n = 3); *p < 0.05, **p < 0.01, or ***p 
< 0.001 for BMDMs cocultured with T cells compared to control BMDMs. n.s.: no significant difference.
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of activating DCs is a promising candidate for TB vaccine 
design, because the Rv2299c-ESAT-6 fusion protein 
significantly reduced the bacterial load in lungs after a 
challenge with the highly virulent Mtb HN878 clinical 
strain.
The fundamental rationale for the development of 
TB vaccines designed to elicit T-cell-based immunity 
is based on the assumption that a strong Th1 immune 
response specifically directed against Mtb antigens is 
the primary mechanism for antituberculosis immunity. 
Antigens that do not elicit Th1 responses uniformly fail to 
protect against Mtb, but not all proteins that induce robust 
Th1 responses after vaccination provide considerable 
protection [27]. The MVA85A vaccine, which elicits a 
robust Th1 response against Ag85A, does not provide 
protection on top of that conferred by BCG in humans 
[28]. It is important to note that a vaccine induces a 
memory T-cell response and facilitates development of 
long-term immunity. DCs play a crucial role in effective 
activation of T cells and induction of memory T-cell 
responses. It is reported that mice vaccinated with Mtb-
infected DCs [29] or Mtb sonicate-pulsed DCs [16] are 
protected against Mtb infection. These results support that 
activating DCs in vivo is crucial in the development of 
Figure 9: CFU counts for each group and histological analysis of representative lung lobes. A. A schematic diagram of 
the experimental design. B. Differences in the bacterial burden among the mice immunized with BCG alone, protein alone, or the BCG/
Rv2299c-ESAT-6 fusion protein and those treated with the adjuvant control (MPL-DDA alone) at 16 weeks after a challenge with Mtb 
HN878 are shown (n = 5 animals/group). C. Lung sections from each immunized mouse were stained with H&E at 16 weeks after challenge 
with Mtb HN878. D. The percentage of the inflamed area from a lung section; *p < 0.05, **p < 0.01, and ***p < 0.001 compared with 
the MPL/DDA-alone group. Group 1 (G1): infection control, G2: MPL/DDA control, G3: BCG alone, G4: BCG/Rv2299c-ESAT-6 fusion 
protein- MPL/DDA, G5: the Rv2299c-ESAT-6 fusion protein- MPL/DDA, G6: ESAT-6- MPL/DDA.
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antimycobacterial vaccine [30]. In this study, to test the 
hypothesis that DC-activating proteins are viable vaccine 
candidates, choosing a reliable DC-activating protein 
was an important research question. First, we selected 
mycobacterial HSPs because they have the ability to 
activate immune cells such as macrophages or DCs [31-
33] and an adjuvant activity [34]. In the present study, 
among the mycobacterial HSPs, we found that Rv2299c 
(HSP90) induces DC maturation through TLR4 signaling 
and MAPK and NF-κB activation. This activation led 
to increased expression of costimulatory molecules and 
secretion of proinflammatory cytokines to promote a Th1-
type immune response. It was recently reported that DCs 
isolated from splenocytes of mice injected with Rv2299c 
show increased expression of MHC molecules and 
costimulatory molecules, and tumor antigen-loaded DCs 
in combination with Rv2299c treatment have a synergistic 
antitumor immunity effect [35]. These results and our 
findings suggest that Rv2299c has an adjuvant activity via 
DC activation in vivo and in vitro.
It has been reported that several mycobacterial 
proteins activate DCs to drive a Th1 immune response 
via the TLR2 [36, 37] or TLR4 pathway [38, 39], or to 
drive a Th2 immune response via the TLR2 pathway [22], 
indicating that each antigen has different effects in DCs. 
Recombinant mycobacterial HSP70 signals through both 
Figure 10: Induction of antigen-specific multifunctional T cells in the lungs of mice after a challenge with Mtb HN878 
strain. Sixteen weeks postinfection, mice in each group (n = 6) were euthanized, and their lung cells (2.0 × 106) were stimulated with each 
antigen (5 μg/ml) for 12 hr at 37°C in the presence of GolgiStop. The percentage of antigen-specific CD4+ T cells producing IFN-γ, TNF-α, 
and/or IL-2 among the cells isolated from a lung of each group of mice were analyzed by multicolor flow cytometry by gating for CD4+ 
lymphocytes. Pie charts represent the mean frequencies of cells coexpressing IFN-γ, TNF-α, and/or IL-2. Data are presented as mean ± SD 
from five mice in each group and unpaired t test was used to determine statistical significance; differences with p < 0.05 were considered 
statistically significant; *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the MPL-DDA-alone group (unpaired t test). Description 
of each group is shown in the legend of Figure 9.
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TLR4 and TLR2, whereas mycobacterial HSP65 signals 
exclusively through TLR4 to activate immune cells [40]. 
Human HSP90 elicits biological activities through the 
TLR4 pathway [41, 42]. The present study showed that 
Rv2299c, which belongs to the HSP90 family, activates 
DCs in a TLR4-, MyD88-, and TRIF-dependent manner, 
which was demonstrated by a pulldown assay and 
experiments on TLR4 or TLR2 knockout mice.
The subunit vaccines consisting of two to four fused 
proteins evoke strong protective responses with efficacy 
that is equivalent to the protection induced by BCG alone 
[26]. Most people have been vaccinated with BCG in 
infancy, but the efficacy of this vaccine wanes over time 
[43], thus boosting the protective immunity induced by 
BCG may be the most practical strategy. Therefore, we 
analyzed the protective immune response and efficacy 
of the fusion protein consisting of Rv2299c and ESAT-6. 
We selected ESAT-6 as a fusion partner because it is one 
of the major antigens included in the vaccines currently 
in clinical trials. ESAT-6 secretion is essential for cell 
death induction in infected cells [44, 45]. In the present 
study, Rv2299c-fused ESAT-6 did not induce cell death, 
thereby suggesting that the fusion protein may lead to 
efficient DC maturation without cytotoxicity. We observed 
similar protective efficacy in mice vaccinated with either 
BCG alone or the fusion protein. It has been suggested 
that memory T-cell recall responses are not dependent 
on DCs and other nonprofessional APCs [46, 47]. 
However, Wakim et al. showed that activation of memory 
T cells in response to systemic or localized infection is 
predominantly dependent on DCs [48, 49]. In the present 
study, the Rv2299c-maturated DCs induced the expansion 
of effector/memory CD4+ T cells from Mtb-infected mice, 
which indicated that Rv2299c might induce memory T-cell 
recall responses in BCG-vaccinated subjects. Moreover, 
Rv2299c incorporation into the fusion protein improved 
the immunogenicity of ESAT-6, thus pointing towards a 
BCG-prime boosting effect of the Rv2299c-ESAT-6 fusion 
protein.
It is reported that BCG vaccination of mice provides 
less protection against W-Beijing isolates than against 
Mtb H37Rv [24]. This isolate causes death and extensive 
lung pathology in infected C57BL/6 mice. Therefore, we 
assessed the protective effect of the Rv2299c-ESAT-6 
fusion protein as a BCG booster against the Mtb HN878 
strain, a hypervirulent W-Beijing-lineage strain, in a 
mouse model. In general, vaccine-induced protection 
against Mtb infection specifically involves antigen-specific 
multifunctional IFN-γ+ TNF-α+ IL-2+ and TNF-α+ IL-2+ 
CD4+ T cells in the lungs [50]. According to these trends, 
Rv2299c can likely function as a central component of a 
successful vaccine against Mtb infection. Immunization 
with the Rv2299c-ESAT-6 fusion, but not with BCG or 
with the stand-alone protein, induced an Rv2299c-fused 
ESAT-6-specific multifunctional CD4+ T-cell response 
in lungs. The ability of the vaccine candidate to induce 
Rv2299c-ESAT-6 fusion-specific multifunctional T-cell 
responses in the lungs after intramuscular injection 
is consistent with the observed protective efficacy. In 
addition, this response induced by immunization with 
the Rv2299c-ESAT-6 fusion protein was maintained up 
to 16 weeks postinfection; this result is suggestive of 
the presence of primed multifunctional memory CD4+ T 
cells and their rapid expansion after the recognition of 
Mtb infection. This finding underscores the importance of 
appropriately adjuvanted-vaccine candidates for induction 
of protective pulmonary immune responses.
In this study, we employed monophosphoryl 
Lipid A (MPL) as an adjuvant for the Rv2299c subunit 
vaccine. However, TRIF-based TLR4 activation by 
MPL [51] may not induce an optimal Th1 immune 
response. A recent study showed that synergistic 
interactions between MyD88 and TRIF are required 
for Th1-cell polarization with a TLR4 agonist adjuvant 
[52]. Accordingly, activation of MyD88 by Rv2299c 
and activation of TRIF by MPL may have synergistic 
interactions to elicit the protective efficacy of the 
Rv2299c-fused ESAT-6 subunit vaccine by enhancing 
Th1 immune responses against Mtb. However, for 
more practical settings, the optimal combination 
between antigens and adjuvant should be evaluated by 
considering their immunological features. In addition, 
mouse immune cells clearly differ from those of 
humans. For example, previous studies demonstrated 
that TLR4 agonists barely induce CD8+ T cells in 
humans because although mouse CD8α+ DCs express 
TLR4, their human counterparts (CD141+ DCs) do not 
[53, 54]. In the same context, the contribution of CD8+ 
T cells has recently been emphasized in protective 
immunity against Mtb infection [55, 56]. Thus, further 
experiments on the comparison of the adjuvant effect 
between TLR4- and TLR3-based adjuvants on the 
vaccine efficacy of the Rv2299c-ESAT-6 fusion should 
be conducted.
Nevertheless, to the best of our knowledge, the 
BCG-prime boosting strategy with a subunit vaccine 
against highly virulent Mtb clinical isolates has not been 
tested to date. Because various studies showed that BCG 
vaccination of mice provides less protection against 
W-Beijing isolates than from Mtb H37Rv isolates [24, 
51], a single dose of parental BCG vaccine is unlikely 
to maintain protective immunity against highly virulent 
strains. Further research is needed to optimize the boosting 
dose and timing to improve the efficacy of this BCG-prime 
boosting strategy. Moreover, to enter clinical testing, 
further study for in vivo toxicity should be investigated. 
In any case, in this study, DC-activating Rv2299c antigen 
and ESAT-6-based subunit vaccine was found to exert a 
durable BCG-prime boosting effect against hypervirulent 
HN878 in mice. In conclusion, our results suggest that 
Rv2299c is an excellent candidate for the rational design 
of an effective multiantigenic TB vaccine.
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MATERIALS AND METHODS
Ethics statement
All animal studies were performed in accordance 
with Korean Food and Drug Administration (KFDA) 
guidelines. The experimental protocols used in this study 
were reviewed and approved by the Ethics Committee 
and Institutional Animal Care and Use Committee 
(Permit Number: 2014-0197-3) of the Laboratory Animal 
Research Center at Yonsei University College of Medicine 
(Seoul, Korea) and IACUC (CNU-00284) of animal care 
at Chungnam National University (Daejeon, Korea).
Bacterial strains and preparation of 
Mycobacterium spp
Mtb H37Rv (ATCC 27294) and H37Ra (ATCC 
25177) were purchased from American Type Culture 
Collection (ATCC, Manassas, VA), and Mtb HN878 was 
obtained from the strain collections of the International 
Tuberculosis Research Center (ITRC, Changwon, 
Gyeongsangnam-do, South Korea). M. bovis BCG 
(Pasteur strain 1173P2) was kindly provided by Dr. Brosch 
at the Pasteur Institute (Paris, France). All mycobacteria 
used in this study were prepared as described previously 
[25].
Animals
Specific pathogen-free 5- to 6-week-old female 
C57BL/6 mice as well as OT-I and OT-II T-cell receptor 
(TCR) transgenic mice (C57BL/6 background), C57BL/6 
(H-2Kb and I-Ab), C57BL/6J TLR2 knockout mice 
(TLR2−/−; B6.129-Tlr2tm1Kir/J), and C57BL/10 TLR4 
knockout mice (TLR4−/−; C57BL/10ScNJ) were purchased 
from the Jackson Laboratory (Bar Harbor, ME, USA). The 
mice were maintained under barrier conditions in a BL-3 
biohazard animal facility at the Yonsei University Medical 
Research Center with constant temperature (24°C ± 1°C) 
and humidity (50% ± 5%). The animals were fed a sterile 
commercial mouse diet with ad libitum access to water 
under standardized light-controlled conditions (12 hr light 
and 12 hr dark periods). The mice were monitored daily, 
and none of the mice showed any clinical symptoms or 
illness during this experiment.
Abs and reagents
Recombinant mouse macrophage colony-stimulating 
factor (M-CSF), granulocyte-macrophage colony 
stimulating factor (GM-CSF), and interleukin 4 (IL-4) 
were purchased from CreaGene (Gyeonggi, Republic of 
Korea). Fluorescein isothiocyanate (FITC)-annexin V/
propidium iodide kits were purchased from R&D Systems 
(Minneapolis, MN, USA). Dextran-FITC (molecular 
mass, 40,000 Da) was acquired from Sigma (St. Louis, 
MO, USA). Lipopolysaccharide (LPS) from Escherichia 
coli O111:B4 was purchased from InvivoGen (San Diego, 
CA, USA). The endotoxin filter (END-X) and endotoxin 
removal resin (END-X B15) were acquired from the 
Associates of Cape Cod (East Falmouth, MA, USA). The 
OT-I peptide (OVA257–264) and OT-II peptide (OVA323–339) 
were synthesized by Peptron (Daejeon, Korea). The anti-
phosphorylated-ERK1/2 monoclonal Ab, anti-ERK1/2 
monoclonal Ab, anti-phosphorylated p38 monoclonal Ab, 
anti-p38 monoclonal Ab, anti-NF-κB (p65) polyclonal Ab, 
anti-phosphorylated IκB-α monoclonal Ab, anti-IκB-α 
monoclonal Ab, anti-lamin B polyclonal Ab, and anti-β-
actin polyclonal Ab were acquired from Cell Signaling 
Technology (Danvers, MA, USA). The HRP-conjugated 
anti-mouse IgG Ab and HRP-conjugated anti-rabbit Ab 
were obtained from Calbiochem (San Diego, CA, USA), 
and the anti-β-actin mAb (AC-15) was purchased from 
Sigma. The FITC-conjugated mAbs against CD11c, p65, 
IFN-γ, and CD62L, the APC-conjugated mAbs against IL-
12p70, IL-10, and CD3, the PerCP-Cy5.5-conjugated mAb 
against CD4 and CD8, the APC-Cy7-conjugated mAb 
against CD8+, the phycoerythrin (PE)-conjugated mAbs 
against CD80, CD86, MHC class I, MHC class II, IFN-γ, 
and CD44, the PE-Cy7-conjugated mAbs against CD11c 
and IL-2, and the eFluor® 450-conjugated mAb against 
CD3e were purchased from eBioscience (San Diego, CA, 
USA). The phycoerythrin (PE)-conjugated rat anti-IgG1, 
rat anti-IgG2a, and rat anti-IgG2b, the APC-conjugated 
rat anti-IgG2a and rat anti-IgG1, the FITC-conjugated rat 
anti-IgG2b, and the PE-Cy7-conjugated mouse anti-IgG1 
and rat anti-IgG2b Abs were obtained from eBioscience. 
These antibodies were used as isotype controls. TNF-α, 
IL-1β, IFN-γ, IL-2, IL-4, IL-6, IL-10, and IL-12p70 
ELISA kits were obtained from eBioscience.
Expression and purification of recombinant 
proteins
To produce a recombinant Rv2299c protein, the 
corresponding gene was amplified by PCR using M. 
tuberculosis H37Rv ATCC27294 genomic DNA as a template 
and the following primers: Rv2299c forward, 5’- CATAT 
GAACGCCCATGTCGAGCAGTTG-3’, and reverse, 5’-GA
ATTCGGCAAGGTACGCGCGAGACGTTC-3’; ESAT-
6 forward, 5’-AAGCTTATGACAGAGCAGCAGTGGA
AT-3’, and reverse, 5’-CTCGAGTGCGAACATCCCAG
TGACGTT-3’. The PCR product of Rv2299c was digested 
with NdeI and EcoRI, and ESAT-6 was cut with HindIII and 
XhoI. The products were inserted into the pET22b (+) vector 
(Novagen, Madison, WI, USA), and the resultant plasmids 
were sequenced. The recombinant plasmids were transfected 
into E. coli BL21 cells by heat-shock for 1 min at 42°C. To 
produce a recombinant fusion protein, the PCR products of 
Rv2299c were inserted into previously produced ESAT-6-
containing pET22b (+) vector. The recombinant protein was 
prepared as previously described [52].
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Cell culture
Murine bone marrow-derived DCs were generated, 
cultured and purified as recently described [52]. Bone 
marrow-derived macrophages (BMDMs) were prepared 
using recombinant M-CSF, as previously described 
[53]. Briefly, bone marrow cells isolated from C57BL/6 
mice were lysed with red blood cell (RBC)-lysing buffer 
(ammonium chloride 4.15 g/500 ml, 0.01 M Tris-HCl 
buffer pH 7.5 ± 2) and washed with the RPMI 1640 
medium. The obtained cells were plated in six-well culture 
plates (106 cells/ml, 3 ml/well) and cultured at 37°C in the 
presence of 5% CO2 in RPMI 1640 media supplemented 
with 100 unit/ml penicillin/streptomycin (Lonza), 10% 
of fetal bovine serum (Lonza), 50 μM mercaptoethanol 
(Lonza), 0.1 mM nonessential amino acids (Lonza), 1 mM 
sodium pyruvate (Sigma), 20 ng/ml GM-CSF, and 10 ng/
ml IL-4 (BMDC) or 20 ng/ml M-CSF (BMDM).
Cytotoxicity analysis
Cytotoxicity analysis was conducted using an 
Annexin V/propidium iodide (PI) staining kit (BD 
Biosciences). The cells were stained with FITC-
conjugated Annexin V and PI. Analysis of the stained cells 
was performed on a FACSCanto II with FACSDiva, and 
the results were analyzed using the FlowJo software (Tree 
Star, Ashland, OR, USA).
Analysis of the expression of surface molecules 
by flow cytometry
On day 6, BMDCs were harvested, washed with 
PBS, and resuspended in FACS washing buffer (2% 
FBS and 0.1% sodium azide in PBS). The cells were 
preincubated with 0.5% BSA in PBS for 30 min and 
washed with PBS. The cells were stained with PE-
conjugated anti-H-2Kb (MHC class I), anti-I-Ab (MHC 
class II), anti-CD80, and anti-CD86 along with FITC-
conjugated anti-CD11c antibodies for 45 min at 4°C. The 
cells were washed three times with PBS and resuspended 
in 500 μl of PBS. The fluorescence was measured by flow 
cytometry and the data were analyzed using CellQuest 
data analysis software.
Antigen uptake ability of BMDCs by Rv2299c
BMDCs (2 × 105 cell) were equilibrated at 37°C 
or 4°C for 45 min and then pulsed with fluorescein-
conjugated dextran at a concentration of 1 mg/ml. Cold 
staining buffer was added to stop the reaction. The cells 
were washed three times, stained with PE-conjugated 
anti-CD11c antibodies, and then analyzed with the 
FACSCanto. Nonspecific binding of dextran to DCs was 
determined by incubation of DCs with FITC-conjugated 
dextran at 4°C, and the resulting background value was 
subtracted from the specific binding values.
Confirmation of LPS decontamination for 
Rv2299c
To confirm that the maturation of DCs induced 
by Rv2299c was not due to contaminating endotoxins 
or LPS in the protein preparations, a pretreatment with 
Polymyxin B (PmB) (Sigma), heat-denaturation, and 
digestion with proteinase K (Sigma) were performed. 
DCs were preincubated with 50 μg/ml PmB for 1 hr at 
room temperature prior to treatment with 100 ng/ml LPS 
and 10 μg/ml Rv2299c. For heat-denaturation, LPS or 
Rv2299c was incubated at 100°C for 1 hr. For digestion 
with proteinase K, LPS or Rv2299c were digested for 1 
hr at 37°C with soluble proteinase K at the concentration 
of 10 μg/ml followed by heating for 15 min at 100°C 
to deactivate the enzyme, and subsequently added to 
BMDCs cultures. After 24 hr, TNF-α and IL-6 levels in the 
supernatant of BMDCs were analyzed using an ELISA.
Confocal laser scanning microscopy
DCs were plated overnight on poly-L-lysine-coated 
glass coverslips. After treatment with Rv2299c, the cells 
were fixed in 4% paraformaldehyde, permeabilized in 
0.1% Triton X-100, and then blocked with 2% bovine 
serum albumin (BSA) in PBS containing 0.1% Tween 
20 (PBS/T) for 2 hr before incubation with 2% BSA in 
PBS/T containing an anti-Rv2299c antibody for 2 hr at 
room temperature. After a wash with PBS/T, the cells were 
reincubated with a Cy-3-conjugated secondary antibody in 
the dark room for 1 hr, and then were stained with 1 μg/ml 
of DAPI for 10 min at room temperature. Cell morphology 
and fluorescence intensity were examined using a confocal 
laser scanning microscope (Zeiss LSM510 Meta; Carl 
Zeiss Ltd, Welwyn Garden City, UK). Images were 
acquired using the LSM510 Meta software and processed 
using the LSM image examiner.
Immunoprecipitation
DCs (107) were incubated with 10 μg/ml Rv2299c for 
6 hr, and cell pellets were lysed with lysis buffer (10 mM 
Tris-HCl [pH 7.4], 1% NP-40, 0.25% sodium deoxycholate, 
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 μg/ml each 
aprotinin, leupeptin, and pepstatin, 1 mM Na3VO4, and 1 
mM NaF). To prevent nonspecific binding, the cell lysates 
were precleared by adding 50 μl of normal serum (Santa 
Cruz) and 100 μl of 50% protein A or G Sepharose bead 
slurry (Invitrogen, Carlsbad, CA) to 1 mg of cell lysates. 
After 2-hr incubation at 4°C, the mixture of beads and cell 
lysates was centrifuged at 10,000 × g for 5 min at 4°C, and 
the supernatant was collected for the subsequent experiment. 
Rv2299c (His)-, TLR2-, and TLR4-associated proteins 
were immunoprecipitated by incubation with protein A or G 
Sepharose for 24 hr at 4°C after incubation with an anti-rat 
IgG Ab as a control Ab for anti-TLR2 and TLR4, an anti-
mouse IgG Ab as a control Ab for the anti-Rv2299c (His) Ab 
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for 1 hr at 4°C. The beads were harvested, washed and boiled 
in 5× sample buffer for 5 min. The proteins were separated by 
SDS-PAGE in a 10% gel followed by transfer of the proteins 
to a polyvinylidene difluoride membrane (Millipore). The 
membranes were further probed with anti-TLR2, anti-TLR4, 
and anti-His Abs as indicated.
Immunoblotting analysis
After stimulation with 10 μg/ml Rv2299c, DCs 
were lysed in 100 ml of lysis buffer containing 50 μM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 
1 mM EDTA, 50 mM NaF, 30 mM Na4PO7, 1 mM 
phenylmethanesulfonyl fluoride, 2 μg/ml aprotinin, and 
1 mM pervanadate. Whole-cell lysate samples were 
resolved on SDS-polyacrylamide gels and then transferred 
onto a nitrocellulose membrane. The membranes were 
blocked in 5% skim milk and incubated with a primary 
Ab for 2 hr, followed by incubation with HRP-conjugated 
secondary Abs for 1 hr at room temperature. Epitopes on 
target proteins including MAPKs and NF-κB recognized 
specifically by Abs were visualized by means of the ECL 
Advance Kit (GE Healthcare, Little Chalfont, UK).
Nuclear extract preparation
Nuclear extracts from cells were prepared as 
follows. DCs were treated with 100 μl of lysis buffer (10 
mM HEPES [pH 7.9], 10 mM KCl, 0.1 mM EDTA, 0.5% 
Nonidet P-40, 1 mM dithiothreitol [DTT], 0.5 mM PMSF) 
on ice for 10 min. After centrifugation at 4000 rpm for 5 
min, the pellet was resuspended in 100 μl of extraction 
buffer (20 mM HEPES [pH 7.9], 400 mM NaCl, 1 mM 
EDTA, 1 mM DTT, 1 mM PMSF) and incubated on ice 
for 30 min. After centrifugation at 12,000 rpm for 10 min, 
the supernatant containing nuclear extracts was collected 
and stored at -80°C until analysis.
Treatment of DCs with pharmacological 
inhibitors for analysis of signaling pathways
All the pharmacological inhibitors were purchased 
from Calbiochem. Dimethyl sulfoxide (Sigma) was added 
to cultures at 0.1% (vol./vol.) as a solvent control. DCs 
were washed with PBS and pretreated with inhibitors 
in the RPMI 1640 medium containing glutamine for 1 
hr prior to treatment with Rv2299c for 24 hr. Inhibitors 
were used at following concentrations: U0126 (10 μM), 
SB203580 (20 μM), SP600125 (10 μM), and Bay11-7082 
(20 μM). In all experiments with the inhibitors, a tested 
concentration was used after careful titration experiments 
assessing the viability of the DCs using an MTT assay.
An in vitro T-cell proliferation assay
Responder T cells, which participate in naïve-T-cell 
reactions, were isolated using a MACS column (Miltenyi 
Biotec) from total mononuclear cells extracted from 
BALB/c mice. Both OVA-specific CD8+ and CD4+ T 
cells, responders, were obtained from splenocytes of OT-1 
and OT-2 mice, respectively. These T cells were stained 
with 1 μM CFSE (Invitrogen) as previously described 
[54]. DCs (2 × 105 cells per well) treated with the OVA 
peptide in the presence of 10 μg/ml of Rv2299c for 24 
hr were cocultured with CFSE-stained CD8+ and CD4+ T 
cells (2 × 106) at DC:T cell ratios of 1:10. On day 3 or 4 
of coculture, each T cell batch was stained with PerCP-
Cy5.5-conjugated anti-CD4+ mAb, PE-Cy5-conjugated 
anti-CD4+ mAb, PE-Cy5-conjugated anti-CD8+ mAb, 
Alexa 647-conjugated anti-CCR3 mAb, or PE-conjugated 
anti-CXCR3 mAb and analyzed by flow cytometry. 
The supernatants were harvested and assayed for the 
production of IFN-γ, IL-2, and IL-4 by ELISAs.
Analysis of the activation of effector/memory 
T cells
As explained above, responder T cells, which 
participate in allogeneic T-cell reactions, were isolated 
using a MACS column (Miltenyi Biotec) from total 
mononuclear cells extracted from M. tuberculosis-infected 
BALB/c mice. Staining with an APC-conjugated anti-
CD3 mAb (BD Biosciences) revealed that the preparation 
consisted mainly of CD3+ cells (>95%). DCs (2 × 105 
cells per well) isolated from wild-type (WT), TLR2−/−, and 
TLR4−/− C57BL/6 mice were treated with Rv2299c for 24 
hr followed by extensive washing and were cocultured 
with 2 × 106 responder allogeneic T cells (M. tuberculosis-
infected T cells) at DC:T cell ratios of 1:10. On 4 d of 
coculture, the cells were stained with PerCP-Cy5.5-
conjugated anti-CD4+ mAb, PerCP-Cy5.5-conjugated 
anti-CD8+ mAb, FITC-conjugated anti-CD62L mAb, and 
PE-conjugated anti-CD44 mAb, and analyzed by means 
of a flow cytometer.
Quantification of cytokines
A sandwich enzyme-linked immunosorbent assay 
(ELISA) was used for detecting IL-6, IL-1β, TNF-α, 
IFN-γ, IL-4, IL-2, IL-12p70, and IL-10 in culture 
supernatants as described previously [52]. Single cells 
prepared from the lungs of the immunized or infected mice 
were stimulated with PPD (2 μg/ml) or antigen-specific 
CD4 or CD8 T cell peptides (2 μg/ml) for 24 hr at 37°C. 
The IFN-γ cytokine levels in the culture supernatant were 
measured using a commercial ELISA kit (eBioscience).
Intracellular cytokine assays
Cells were first blocked with 10% (vol./vol.) 
normal goat serum for 15 min at 4°C and then stained 
with FITC-conjugated CD11c+ antibody for 30 min at 
4°C. Cells stained with the appropriate isotype-matched 
immunoglobulin (Ig) served as negative controls. The cells 
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were fixed and permeabilized with the Cytofix/Cytoperm 
kit (BD Biosciences). Intracellular IL-12p70, IL-10, IL-2, 
IL-4, and IFN-γ were detected with fluorescein-conjugated 
antibodies (BD Biosciences) in a permeation buffer. For 
intracellular cytokine staining, single-cell suspensions 
from immunized animals (2 × 106 cells) were stimulated 
with each antigen (5 μg/ml) for 12 hr at 37°C in the 
presence of GolgiStop (BD Biosciences). The cells were 
first blocked with Fc Block (anti-CD16/32) for 15 min at 
4°C and then stained with BV421-conjugated anti-CD3, 
PerCp-Cy5.5-conjugated anti-CD4, and FITC-conjugated 
anti-CD62L antibodies for 30 min at 4°C. These cells 
were fixed and permeabilized with the Cytofix/Cytoperm 
kit (BD Biosciences). Intracellular TNF-α, IL-2, and 
IFN-γ were detected using APC-conjugated anti-TNF-α, 
PE-Cy7-conjugated anti-IL-2, and PE-conjugated anti-
IFN-γ antibodies in a permeation buffer. All antibodies 
were purchased from eBioscience (San Diego, CA) unless 
otherwise stated. The cells were analyzed on a FACSverse 
flow cytometer using the commercially available software 
program FlowJo (Treestar, Inc., San Carlos, CA).
Measurement of intracellular Mtb growth in 
macrophages
Adherent BMDMs (2 × 105 cells/well) were washed 
twice in PBS and infected in triplicate with Mtb at 2 × 
105 bacilli/well. Tubercle bacilli and macrophages were 
incubated for 4 hr. Then, the infected BMDMs were treated 
with amikacin (200 μg/ml) for 2 hr. After 2 hr, monolayers 
were washed to remove extracellular bacilli, and this time 
point was considered day 0. Next, a previously prepared 
mixture was added to each well, and the plate was 
incubated for 3 days. The mixture was antigen-activated 
DCs cocultured with CD4+ T cells at a DC:T cell ratio of 
1:10 for 3 days. DC-activating antigens were LPS (100 
ng/ml) and Rv2299c (10 μg/ml). The number of ingested 
and internalized Mtb within the BMDM was calculated by 
lysing the infected cells from one of the wells in distilled 
water. The Tubercle bacilli counts of the inoculum were 
then checked by serial dilution and plating on 7H10 
agar with 10% Middlebrook OADC supplement (Difco, 
Detroit, MI). The plates were incubated at 37°C for 3 
weeks. At the end of the 3 weeks, plates were taken out 
and colony forming units (CFUs) were calculated from the 
number of colonies of Mtb.
Vaccination and a challenge in mice
For vaccination, mice were immunized with 
BCG Pasteur 1173P2 via subcutaneous injection 
(2.0 × 105 CFUs/mouse) first, then after 6 weeks post-
BCG immunization, each subunit vaccine (2 μg) 
was given three times at 3-weeks intervals with 
dimethyldioctadecylammonium (DDA) liposomes (50 
μg/injection) containing monophosphoryl lipid-A (MPL, 
5 μg/injection) (MPL-DDA). Four weeks after the final 
immunization, the immunized mice were aerogenically 
challenged with the Mtb HN878 strain as previously 
described [25, 55]. Briefly, mice were exposed to a 
predetermined dose of H37Rv or HN878 for 60 min in 
the inhalation chamber of an airborne infection apparatus 
(Glas-Col, Terre Haute, IN, USA) to expose the mice to 
approximately 200 CFUs of viable Mtb. At 16 weeks 
postchallenge, spleen and lung cells were harvested from 
each group, and the frequencies of multifunctional T cells 
and T-cell subtypes were assessed using flow cytometry.
Bacterial counts and histopathological analysis
Sixteen weeks after the HN878 challenge, 
six to seven mice per group were euthanized by 
CO2 asphyxiation, and the lungs and spleens were 
homogenized. The number of viable bacteria was 
determined by plating serial dilutions of the organ (left 
lung or half spleen) homogenates onto Middlebrook 
7H11 agar (Difco Laboratories, Detroit, MI) 
supplemented with 10% OADC (Difco Laboratories), 
amphotericin B (Sigma-Aldrich, St. Louis, MO) and 
2 μg/ml 2-thiophenecarboxylic acid hydrazide (Sigma-
Aldrich). Colonies were counted after 4 weeks of 
incubation at 37°C. For the histopathological analysis, 
the superior lobes of the right lung were stained with 
H&E and assessed for the severity of inflammation. 
The level of inflammation in the lungs was evaluated 
using the ImageJ software (National Institutes of 
Health, Bethesda, MD), as described previously [56]. 
In addition, the inflammatory responses were assessed 
based on lesion size and constitution of immune cells. 
The data on CFUs and assessment of lung inflammation 
are reported as the median log10 CFU ± interquartile 
range (IQR).
Statistical analysis
All the experiments were repeated at least three 
times with consistent results. The levels of significance 
for comparison between samples were determined by 
Tukey’s multiple comparison test distribution using 
statistical software (GraphPad Prism Software, version 
4.03; GraphPad Software, San Diego, CA). The data in 
the graphs are expressed as the mean ± SEM. Differences 
with each value of *p < 0.05, **p < 0.01, or ***p < 0.001 
were considered statistically significant.
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